Merck's odanacatib flies over Phase III hurdle
This article was originally published in Scrip
Executive Summary
A Phase III trial of Merck & Co's novel investigational treatment for osteoporosis odanacatib has been closed early after a planned interim analysis showed better than expected efficacy, raising hopes that the product will prove a worthy successor to Merck's previous blockbuster bisphosphonate Fosamax (alendronate).